BeiGene, Ltd. (NASDAQ:BGNE) SVP Chan Henry Lee Sells 1,202 Shares

BeiGene, Ltd. (NASDAQ:BGNE) SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, July 30th, Chan Henry Lee sold 834 shares of BeiGene stock. The stock was sold at an average price of $160.57, for a total value of $133,915.38.

BeiGene Trading Up 1.1 %

Shares of NASDAQ BGNE traded up $2.62 during mid-day trading on Wednesday, hitting $233.60. 410,278 shares of the company traded hands, compared to its average volume of 251,713. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $238.80. The stock has a market capitalization of $22.64 billion, a price-to-earnings ratio of -30.86 and a beta of 0.61. The business has a 50 day moving average of $190.73 and a two-hundred day moving average of $166.90.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, beating analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company had revenue of $929.20 million during the quarter, compared to analyst estimates of $810.34 million. During the same period in the prior year, the firm earned ($3.64) earnings per share. The business’s quarterly revenue was up 56.1% on a year-over-year basis. On average, sell-side analysts anticipate that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BGNE. JMP Securities began coverage on BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target for the company. Bank of America decreased their target price on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research note on Tuesday, July 9th. JPMorgan Chase & Co. boosted their price target on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, Citigroup raised their price objective on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and an average target price of $241.21.

Hedge Funds Weigh In On BeiGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James & Associates boosted its position in shares of BeiGene by 0.4% in the second quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock worth $3,035,000 after buying an additional 76 shares during the period. Truist Financial Corp boosted its position in BeiGene by 10.1% during the 2nd quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after acquiring an additional 140 shares during the period. Parkwood LLC grew its stake in BeiGene by 3.0% during the 4th quarter. Parkwood LLC now owns 6,464 shares of the company’s stock valued at $1,166,000 after acquiring an additional 191 shares in the last quarter. ProShare Advisors LLC grew its stake in BeiGene by 8.1% during the 1st quarter. ProShare Advisors LLC now owns 2,902 shares of the company’s stock valued at $454,000 after acquiring an additional 217 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of BeiGene by 51.5% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after purchasing an additional 279 shares during the period. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.